Literature DB >> 6507456

Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis.

M Peters-Golden, R A Wise, M C Hochberg, M B Stevens, F M Wigley.   

Abstract

In order to determine the predictive value of lung function studies for subsequent prognosis in systemic sclerosis, 71 patients with systemic sclerosis were followed up for a mean of five years after pulmonary function testing. A carbon monoxide diffusing capacity less than or equal to 40 percent of the predicted reference value was associated with only a 9 percent five-year cumulative survival rate compared with a 75 percent cumulative five-year survival in patients with a carbon monoxide diffusing capacity greater than 40 percent of predicted. An obstructive ventilatory defect was also associated with increased mortality, and all six patients with obstruction and a diffusing capacity less than 70 percent of the predicted died during the study period. Male gender, independent of abnormalities of pulmonary function, was also associated with a poor prognosis. Although it is not clear whether a severely impaired diffusing capacity is indicative of interstitial pulmonary fibrosis or pulmonary vasculopathy or is a marker of generalized vascular disease, a severely depressed carbon monoxide diffusing capacity is an important predictor of mortality in patients with systemic sclerosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6507456     DOI: 10.1016/0002-9343(84)90183-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  15 in total

1.  Systemic sclerosis in the elderly.

Authors:  L Czirják; Z Nagy; G Szegedi
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

2.  Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.

Authors:  Lorinda Chung; Juliana Liu; Lori Parsons; Paul M Hassoun; Michael McGoon; David B Badesch; Dave P Miller; Mark R Nicolls; Roham T Zamanian
Journal:  Chest       Date:  2010-05-27       Impact factor: 9.410

Review 3.  Interstitial lung disease in systemic sclerosis.

Authors:  O Kaloudi; I Miniati; S Alari; M Matucci-Cerinic
Journal:  Intern Emerg Med       Date:  2007-12-17       Impact factor: 3.397

4.  Interpretation of pulmonary function test: issues and controversies.

Authors:  Cristine E Berry; Robert A Wise
Journal:  Clin Rev Allergy Immunol       Date:  2009-03-21       Impact factor: 8.667

5.  Spontaneous pneumothorax in a patient with systemic sclerosis.

Authors:  M Zeuner; U Müller-Ladner; V D Mohr; B Lang
Journal:  Clin Rheumatol       Date:  1996-03       Impact factor: 2.980

Review 6.  The current state of biomarkers in systemic sclerosis.

Authors:  Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

7.  Severe spirometric defects in systemic lupus erythematosus. A possible role for bronchoalveolar lavage and gallium scanning.

Authors:  R Y Lin
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

8.  Changes in estimated right ventricular systolic pressure predict mortality and pulmonary hypertension in a cohort of scleroderma patients.

Authors:  Ami A Shah; Shang-En Chung; Fredrick M Wigley; Robert A Wise; Laura K Hummers
Journal:  Ann Rheum Dis       Date:  2012-08-11       Impact factor: 19.103

9.  HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities.

Authors:  M Bellia; F Cannizzaro; N Scichilone; M Riili; G Triolo; M Midiri; R Lagalla
Journal:  Radiol Med       Date:  2009-03-05       Impact factor: 3.469

10.  Long-term follow-up study of 164 patients with definite systemic sclerosis: classification considerations.

Authors:  M Vayssairat; N Baudot; N Abuaf; C Johanet
Journal:  Clin Rheumatol       Date:  1992-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.